Drug cocktail before surgery may cut liver cancer recurrence

NCT ID NCT07518706

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combination followed by surgery, or surgery alone. The main goal is to see if the combo improves one-year recurrence-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (immunotherapy) and lenvatinib (targeted therapy)
What this could lead to: If successful, this combination before surgery could lower the chance of liver cancer coming back after surgery, improving long-term survival.
What could go wrong: This is a small, early-phase study (60 people) and results may not apply to all patients. The drugs can cause side effects like fatigue, high blood pressure, or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.